Cdk2 Inhibitor II

CAS No. 222035-13-4

Cdk2 Inhibitor II( —— )

Catalog No. M34895 CAS No. 222035-13-4

Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 160 Get Quote
5MG 202 Get Quote
10MG 306 Get Quote
25MG 495 Get Quote
50MG 707 Get Quote
100MG 945 Get Quote
500MG 1872 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cdk2 Inhibitor II
  • Note
    Research use only, not for human use.
  • Brief Description
    Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.
  • Description
    CDK2-IN-3 (compound 3) is a potent and selective CDK2 inhibitor with an 50 of 60 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    222035-13-4
  • Formula Weight
    395.23
  • Molecular Formula
    C14H11BrN4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (253.02 mM; Ultrasonic )
  • SMILES
    N(NC1=CC=C(S(N)(=O)=O)C=C1)=C2C=3C(NC2=O)=CC=C(Br)C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. S T Davis, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science. 2001 Jan 5;291(5501):134-7. ?
molnova catalog
related products
  • Cdc7-IN-5

    Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase. Cdc7, a serine-threonine protein kinase enzyme, is essential for the initiation of DNA replication in the cell cycle.

  • (R)-Enitociclib

    (R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.

  • XPW1

    XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma.